Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI reads MRI scans to predict who will benefit from chemo

NCT ID NCT07702708

Recruiting now Diagnosis Sponsor: Fujian Cancer Hospital Source: ClinicalTrials.gov ↗

First seen Jul 14, 2026 · Last updated Jul 15, 2026 · Updated 1 time

Summary

This study tests whether an artificial intelligence model can predict which patients with HR+/HER2- breast cancer will benefit most from chemotherapy given before surgery. Researchers will use pre-treatment MRI scans to classify patients into high- or low-benefit groups and compare their outcomes, such as residual cancer after treatment. The goal is to personalize chemotherapy decisions and avoid unnecessary treatment for those unlikely to respond.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Pre-treatment DCE-MRI-based AI model
What this could lead to
If successful, this AI tool could help doctors identify which patients with HR+/HER2- breast cancer are most likely to benefit from chemotherapy before starting treatment, potentially sparing others from unnecessary side effects.
What could go wrong
This is an observational study, not a treatment trial, so it does not directly test a new therapy. The AI model's predictions need to be validated against historical data and may not improve outcomes in practice.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

breast neoplasm hormone receptor-positive breast cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BREAST NEOPLASMS HR+/HER2- BREAST CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Fujian Cancer Hospital

    RECRUITING

    Fuzhou, Fujian, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Fujian Provincial Hospital

    RECRUITING

    Fuzhou, Fujian, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ningde First Hospital

    RECRUITING

    Ningde, Ningde, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Sanming Second Hospital

    RECRUITING

    Sanming, Sanming, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Second Affiliated Hospital of Fujian Medical University

    RECRUITING

    Quanzhou, Fujian, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.